Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Hui Nie

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0447-8138; OpenAlex author ID A5086544049. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
34
Papers, trials and grants by year

2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 4 papers · 2025: 2 papers

Papers 12

  1. Reciprocal tumor-platelet interaction through the EPHB1-EFNB1 axis in the liver metastatic niche promotes metastatic tumor outgrowth in pancreatic ductal adeno… Co-author DOI 10.1002/cac2.12637↗
  2. HERVH-derived eRNA activates a super-enhancer-driven ALDH1A3/SAT1 axis to promote ferroptosis escape and pancreatic cancer development. Co-author DOI 10.1126/sciadv.aea9074↗
  3. Retraction Note: Vacuolar protein sorting 35 (VPS35) acts as a tumor promoter via facilitating cell cycle progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s10142-024-01383-2↗
  4. Progesterone receptor potentiates macropinocytosis through CDC42 in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41389-024-00512-7↗
  5. Prolactin receptor potentiates chemotherapy through miRNAs-induced G6PD/TKT inhibition in pancreatic cancer. Last author DOI 10.1096/fj.202302287rr↗
  6. A Nutrient-Deficient Microenvironment Facilitates Ferroptosis Resistance via the FAM60A-PPAR Axis in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.34133/research.0300↗
  7. Vacuolar protein sorting 35 (VPS35) acts as a tumor promoter via facilitating cell cycle progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s10142-023-01020-4↗
  8. A low amino acid environment promotes cell macropinocytosis through the YY1-FGD6 axis in Ras-mutant pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41388-021-02159-9↗
  9. Diet-Induced Obesity Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma via CX3CL1/CX3CR1 Axis. Co-author DOI 10.1155/2022/5665964↗
  10. The short isoform of PRLR suppresses the pentose phosphate pathway and nucleotide synthesis through the NEK9-Hippo axis in pancreatic cancer. Co-author DOI 10.7150/thno.51712↗
  11. GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca2+ signalling in a GAB… Co-author DOI 10.1136/gutjnl-2018-317479↗
  12. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy. Co-author DOI 10.21037/cco.2019.03.02↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yan-Zhi Gai · 7 shared papers, 2022–2024 · strength 1.30
  2. Xiaomei Yang · 6 shared papers, 2019–2025 · strength 0.84
  3. Xueli Zhang · 6 shared papers, 2019–2025 · strength 0.83
  4. Shu‐Heng Jiang · 6 shared papers, 2019–2025 · strength 0.81
  5. Zhigang Zhang · 5 shared papers, 2019–2025 · strength 0.59
  6. Yingna Liao · 3 shared papers, 2023–2024 · strength 0.58
  7. Ying-Na Liao · 2 shared papers, 2024 · strength 0.45
  8. Yifan Zhang · 3 shared papers, 2021–2024 · strength 0.44
  9. Li-Peng Hu · 4 shared papers, 2019–2022 · strength 0.39
  10. Dong‐Xue Li · 2 shared papers, 2022–2025 · strength 0.36
  11. Linli Yao · 2 shared papers, 2022–2025 · strength 0.32
  12. Yongwei Sun · 3 shared papers, 2019–2022 · strength 0.29
  13. Dianhui Wei · 1 shared paper, 2025 · strength 0.25
  14. Lili Yuan · 1 shared paper, 2025 · strength 0.25
  15. Boshi Wang · 1 shared paper, 2025 · strength 0.25
  16. Hong Pan · 1 shared paper, 2024 · strength 0.23
  17. Yan‐Miao Huo · 1 shared paper, 2024 · strength 0.23
  18. Qing Li · 2 shared papers, 2021–2022 · strength 0.23
  19. Hui Li · 1 shared paper, 2024 · strength 0.18
  20. Qin Yang · 2 shared papers, 2019–2021 · strength 0.17
  21. Hui Li · 1 shared paper, 2023 · strength 0.16
  22. Shan Zhang · 1 shared paper, 2023 · strength 0.16
  23. Yue Sun · 1 shared paper, 2022 · strength 0.16
  24. Dongxue Li · 1 shared paper, 2022 · strength 0.12
  25. Dejun Liu · 1 shared paper, 2022 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.